**Suppl. Figure 1.** BAFF level in MS patients’ sera is elevated under anti-CD20 therapy but is not associated with clinical or radiological disease parameters.

**A.** Concentration of B cell-activating factor of the tumor necrosis factor family (BAFF) in MS patients related to treatment: “anti-CD20” (rituximab and ocrelizumab), “other DMT”, and “no DMT” (Suppl. Table). **B.** Correlations heatmap: level of fatigue (FIS), its subdimensions, sleepiness (ESS), and depression (GRID-HAMD-21) in relation to mean BAFF serum concentrations in different treatment groups (BAFF - total, BAFF - anti-CD20, BAFF - other DMT, BAFF - no DMT). Colors are coded for Spearman’s correlation coefficient rho from -0.5 to 0.5. **C.** Serum BAFF levels of MS patients that are grouped according to the treatment and clinical course - relapsing-remitting MS (RRMS) and chronic progressive MS (CPMS). DMT = disease-modifying therapy; \* p < 0.05, \*\*\* p < 0.001, n.s. = not significant